Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $103.18 (market cap $29.07B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is far larger — about 3.9× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 126 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LQD | SYRE | |
|---|---|---|
Market Cap | $29.07B | $7.52B |
Volume | 26,122,352 | 1,441,031 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $108.92 |
52-Week Low | $101.83 | $22.18 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.55, down slightly by 0.03% on the day, with technical indicators signaling a bearish trend as selling pressure outweighs buying. The ETF faces headwinds from rising bond yields and increased short interest, which grew 53.1% in September. Recent dividends of $0.44-$0.46 provide income support, but the overall market sentiment remains cautious amid a challenging fixed-income environment.
The outlook for LQD is constrained by persistent bond market volatility and higher interest rates, which pressure corporate bond valuations. While the ETF's investment-grade portfolio offers relative safety, further yield increases could limit upside. Key risks include Fed policy uncertainty and economic slowdown concerns, warranting a neutral to cautious stance for equity-focused investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
